



an Open Access Journal by MDPI

New Vaccine Technologies and Approaches 2.0

Guest Editors:

Dr. Stephen A. Morris

The Future Vaccine
Manufacturing Research Hub,
Department of Biochemical
Engineering, University College
London, Bernard Katz Building,
London WC1E 6BT, UK

Dr. Camila Coelho

Laboratory of Malaria
Immunology and Vaccinology,
NIAID, NIH- Bethesda, MD, USA

Deadline for manuscript
submissions:

closed (15 December 2021)

Message from the Guest Editors

The urgent global need for vaccines to prevent COVID-19, allied with the rapid development of immunization approaches targeting SARS-CoV-2, evidences how the vaccinology field has substantially evolved lately. New technologies for antigen design, the rapid discovery of high neutralizing monoclonal antibodies and the development of new delivery platforms are only a few examples. In addition, in recent years, innumerable changes have occurred in terms of density, age and traveling habits of the world population. Thus, changes in vaccine development that can address all these issues need to be implemented.

This Special Issue aims to gather the latest research on new vaccine technologies and approaches, including, but not limited to, the following topics:

1. Adjuvants;
2. Antigen design;
3. Delivery platforms;
4. Nanoparticle viral vectors;
5. Vaccine development for outbreaks;
6. Immunization with whole organisms;
7. DNA vaccines;
8. RNA vaccines;
9. Genetic adjuvants.

We look forward to your contribution to this Special Issue!



mdpi.com/si/61376

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)